Shares

8 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2020

Feb 12, 2021

SELL
$86.91 - $108.33 $22.9 Million - $28.6 Million
-263,679 Closed
0 $0
Q3 2020

Nov 13, 2020

BUY
$96.16 - $135.15 $10.2 Million - $14.4 Million
106,199 Added 67.44%
263,679 $25.4 Million
Q2 2020

Aug 14, 2020

BUY
$85.09 - $130.36 $3.99 Million - $6.12 Million
46,912 Added 42.43%
157,480 $19.2 Million
Q1 2020

May 15, 2020

BUY
$75.11 - $113.76 $5.93 Million - $8.98 Million
78,965 Added 249.87%
110,568 $9.57 Million
Q3 2019

Nov 14, 2019

BUY
$83.82 - $101.5 $16,764 - $20,300
200 Added 0.64%
31,603 $2.85 Million
Q4 2018

Feb 14, 2019

BUY
$68.32 - $124.36 $25,210 - $45,888
369 Added 1.19%
31,403 $2.24 Million
Q3 2018

Nov 14, 2018

BUY
$98.88 - $125.85 $131,905 - $167,883
1,334 Added 4.49%
31,034 $3.82 Million
Q2 2018

Aug 14, 2018

BUY
$75.3 - $105.99 $2.24 Million - $3.15 Million
29,700 New
29,700 $2.92 Million

Others Institutions Holding NBIX

About NEUROCRINE BIOSCIENCES INC


  • Ticker NBIX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 95,639,296
  • Market Cap $12.3B
  • Description
  • Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...
More about NBIX
Track This Portfolio

Track Bamco Inc Portfolio

Follow Bamco Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Bamco Inc , based on Form 13F filings with the SEC.

News

Stay updated on Bamco Inc with notifications on news.